ORKA-001 Week 28 Data Shows Deepening Psoriasis Clearance Without Additional Dosing
ORKA has more than doubled off its 52-week low of $14.89.
Summary
Oruka Therapeutics reported positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. PASI 100 response rates increased to 71.4% and PASI 90 to 87.3%, despite no dosing after Week 4. Placebo crossover patients achieved similar response rates, and safety remained consistent with the IL-23 class. This data strengthens the case for ORKA-001 as a potential best-in-class therapy with infrequent dosing. Upcoming catalysts include 52-week EVERLAST-A data in December 2026 and 16-week EVERLAST-B data in 4Q 2026.
Updates
· Seeking Alpha — Oruka shares fell after the Week 28 data, with PASI 100 at 71% (vs 64% at Week 16) falling short of investor expectations. Safety showed two unrelated serious adverse events.
At the time of this announcement, ORKA was trading at $96.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $14.89 to $115.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.